Blog

Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

Open filters
Search
Tags
Author
Aditi Singhai
Alison Sathe
Anders Vinther
Anne-Caroline Boillot
Barbara W. Unger
Barry Price
Jackie Torfin
Jerry Chapman
Jon Falker
Katie Terry
Khushboo Agrawal
Mark Agostino
Michael de la Torre
Rebecca Stauffer
Redica Systems
Roger Angarita
Sarah Boynton
Scott Sherrill
Tashil Sharma
Subscribe to our Newsletter
Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.
Trends

Part 1: How to Stop the Data Integrity Excuses

No items found.

How to Respond to FDA 483s

No items found.
Enforcement

6 Features to Look for in FDA 483s

No items found.
Trends

“It was the Best Advice Because it was the Worst Advice”

No items found.
Trends

Why Isn’t Paper the Same as Electronic?

No items found.
Trends

FDA Draft Guidance on Multiple Entity Registration Requirements

No items found.

A Bad 483 Could Cost a Company Millions

No items found.
Trends

NASDA and FDA Work Together to Implement the Produce Safety Rule

No items found.
Trends

FINAL Part 3: Invisible Ink in GLP and GCP Research

No items found.

The New FDA GMP Inspection Model

No items found.
Trends

Part 2: Invisible Ink in GLP and GCP Research

No items found.
Trends

Part 3: Drug GMP Warning Letters Data Integrity

No items found.
Trends

Part 1: Invisible Ink in GLP and GCP Research

No items found.
Trends

Part 2: Drug GMP Warning Letters Data Integrity

No items found.
Trends

Follow the Trail to Find Data Integrity Problems

No items found.

Who Can See Form FDA 483s, and Where Do I Get Them?

No items found.
Trends

Part 1: Drug GMP Warning Letters Data Integrity

No items found.
Trends

How Do I Apply ALCOA To E-Records?

No items found.